Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer

This study explored the clinical implications of tumor mutational burden (TMB) in a well-defined HER2-positive metastatic breast cancer (MBC) patient population who had been previously treated but had subsequent disease progression. Whole exome sequencing was performed on formalin-fixed paraffin-emb...

Celý popis

Podrobná bibliografia

Vydané v:	Oncoimmunology Ročník 7; číslo 8; s. e1466768
Hlavní autori:	Park, Song Ee, Park, Kyunghee, Lee, Eunjin, Kim, Ji-Yeon, Ahn, Jin Seok, Im, Young-Hyuck, Lee, Choonghoon, Jung, Hun, Cho, Soo Youn, Park, Woong-Yang, Cristescu, Razvan, Park, Yeon Hee
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Taylor & Francis 01.01.2018 Taylor & Francis Group
Predmet:	Human epidermal growth factor receptor 2 (HER2) Long survival outcomes Metastatic breast cancer (MBC) Original Research Tumor mutational burden (TMB) whole exome sequencing (WES) Human epidermal growth factor receptor 2 (HER2) Metastatic breast cancer (MBC) Tumor mutational burden (TMB) Long survival outcomes whole exome sequencing (WES)
ISSN:	2162-402X, 2162-4011, 2162-402X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!